RU2711380C2 - Новый подход к лечению рака с применением иммуномодуляции - Google Patents

Новый подход к лечению рака с применением иммуномодуляции Download PDF

Info

Publication number
RU2711380C2
RU2711380C2 RU2018105985A RU2018105985A RU2711380C2 RU 2711380 C2 RU2711380 C2 RU 2711380C2 RU 2018105985 A RU2018105985 A RU 2018105985A RU 2018105985 A RU2018105985 A RU 2018105985A RU 2711380 C2 RU2711380 C2 RU 2711380C2
Authority
RU
Russia
Prior art keywords
cancer
paragraphs
antibody
administered
dose
Prior art date
Application number
RU2018105985A
Other languages
English (en)
Russian (ru)
Other versions
RU2018105985A3 (enExample
RU2018105985A (ru
Inventor
Вимал Д. МЕХТА
Лука РАСТЕЛЛИ
Апарна Каточх САПРА
Original Assignee
Байоксэл Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоксэл Терапьютикс, Инк. filed Critical Байоксэл Терапьютикс, Инк.
Publication of RU2018105985A3 publication Critical patent/RU2018105985A3/ru
Publication of RU2018105985A publication Critical patent/RU2018105985A/ru
Application granted granted Critical
Publication of RU2711380C2 publication Critical patent/RU2711380C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
RU2018105985A 2015-07-16 2016-07-18 Новый подход к лечению рака с применением иммуномодуляции RU2711380C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562193348P 2015-07-16 2015-07-16
US62/193,348 2015-07-16
US201562204495P 2015-08-13 2015-08-13
US62/204,495 2015-08-13
PCT/US2016/042798 WO2017011831A1 (en) 2015-07-16 2016-07-18 A novel approach for treatment of cancer using immunomodulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2019144144A Division RU2817047C2 (ru) 2015-07-16 2016-07-18 Новый подход к лечению рака с применением иммуномодуляции

Publications (3)

Publication Number Publication Date
RU2018105985A3 RU2018105985A3 (enExample) 2019-08-16
RU2018105985A RU2018105985A (ru) 2019-08-16
RU2711380C2 true RU2711380C2 (ru) 2020-01-16

Family

ID=57757732

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018105985A RU2711380C2 (ru) 2015-07-16 2016-07-18 Новый подход к лечению рака с применением иммуномодуляции

Country Status (15)

Country Link
US (3) US11564986B2 (enExample)
EP (1) EP3322448A4 (enExample)
JP (1) JP7032311B2 (enExample)
KR (1) KR20180036974A (enExample)
CN (3) CN116059219A (enExample)
AU (3) AU2016293674B2 (enExample)
BR (1) BR112018000917A2 (enExample)
CA (1) CA2991628C (enExample)
HK (1) HK1248115A1 (enExample)
MA (1) MA42459A (enExample)
MX (2) MX2018000619A (enExample)
NZ (1) NZ739503A (enExample)
RU (1) RU2711380C2 (enExample)
WO (1) WO2017011831A1 (enExample)
ZA (2) ZA201800688B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016019232A1 (en) 2014-08-01 2016-02-04 John Vasilakos Methods and therapeutic combinations for treating tumors
CN116059219A (zh) 2015-07-16 2023-05-05 比奥克斯塞尔医疗股份有限公司 一种使用免疫调节治疗癌症的新颖方法
CA3009527C (en) 2015-12-24 2024-01-09 Stephen WILLINGHAM Methods of treating cancer
US11583516B2 (en) * 2016-09-07 2023-02-21 Trustees Of Tufts College Dash inhibitors, and uses related thereto
AU2017339856B2 (en) * 2016-10-06 2024-09-05 Merck Patent Gmbh Dosing regimen of avelumab for the treatment of cancer
US11613785B2 (en) 2017-01-09 2023-03-28 Onkosxcel Therapeutics, Llc Predictive and diagnostic methods for prostate cancer
AU2018244351A1 (en) * 2017-03-28 2019-10-17 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin expression to potentiate immunotherapy
EP3606531A4 (en) 2017-04-04 2021-04-28 Corvus Pharmaceuticals, Inc. METHOD OF TREATMENT OF CANCER
US11559537B2 (en) 2017-04-07 2023-01-24 Trustees Of Tufts College Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists
WO2019094916A1 (en) * 2017-11-13 2019-05-16 Bioxcel Therapeutics, Inc. Methods and compositions for treating cancer by modifying multiple arms of the immune system
JP2021506972A (ja) 2017-12-15 2021-02-22 プラクシス バイオテック エルエルシー 線維芽細胞活性化タンパク質の阻害剤
WO2019202473A1 (en) * 2018-04-16 2019-10-24 Université de Lausanne Ucp2 inducing agents for the treatment of cancer resistant to immune checkpoint blockade
US20210401926A1 (en) * 2018-09-28 2021-12-30 Canimguide Therapeutics Ab Pharmaceutical formulations of peptide inhibitors
GB201819853D0 (en) * 2018-12-05 2019-01-23 Innovation Ulster Ltd Therapy
US20220089733A1 (en) * 2018-12-10 2022-03-24 Bioxcel Therapeutics, Inc. Novel approach for treatment of cancer using immunomodulation
EP3893888A4 (en) * 2018-12-10 2022-08-31 Bioxcel Therapeutics, Inc. COMBINATION THERAPIES FOR TREATING DISEASES USING AN INNATE IMMUNITY MODIFIER AND AN OX40 AGONIST
WO2020132661A2 (en) 2018-12-21 2020-06-25 Praxis Biotech LLC Inhibitors of fibroblast activation protein
EP3908285A4 (en) 2019-01-07 2022-10-19 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
JP2023514056A (ja) * 2020-02-07 2023-04-05 バイオエクセル セラピューティクス，インコーポレイテッド 免疫調節を使用した癌の治療レジメン
EP4104062A4 (en) * 2020-02-14 2024-04-24 Bioxcel Therapeutics, Inc. SYSTEMS AND METHODS FOR DETECTING AND PREVENTING THE OCCURENCE OF UNREST
IL296403A (en) * 2020-03-13 2022-11-01 Univ Texas Sequential cancer treatment using 6-thio-dg, checkpoint inhibitors and radiation therapy
EP4147053B1 (en) * 2020-05-07 2026-01-28 Institut Curie Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
US20220257759A1 (en) * 2021-02-17 2022-08-18 Bioxcel Therapeutics, Inc. Treatment of sarcoma using immunomodulation
TW202345857A (zh) * 2022-03-08 2023-12-01 美商昂科斯克塞爾醫療有限責任公司 他波司他之穩定調配物
US20250186446A1 (en) * 2022-03-11 2025-06-12 Intra-Cellular Therapies, Inc. Organic compounds
WO2024107832A2 (en) * 2022-11-16 2024-05-23 Onkosxcel Therapeutics, Llc Treatment regimen for treating cancers
WO2024155790A2 (en) * 2023-01-18 2024-07-25 Onkosxcel Therapeutics, Llc Novel approach for treatment of cancer using immunomodulation
WO2025076445A1 (en) * 2023-10-04 2025-04-10 Agenus Inc. Anti-fap antibodies and methods of use thereof
CN117482249B (zh) * 2023-11-28 2024-09-17 辽宁中医药大学 一种肝癌干细胞niche响应型逐级靶向脂质体及其应用
CN117695397A (zh) * 2024-02-06 2024-03-15 北京肿瘤医院(北京大学肿瘤医院) 用于提高肿瘤靶向cldn18.2治疗疗效的药物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127204A2 (en) * 2006-04-24 2007-11-08 Dara Biosciences, Inc. Methods and compositions relating to immunostimulation
WO2014144600A2 (en) * 2013-03-15 2014-09-18 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
US20140271725A1 (en) * 2011-11-22 2014-09-18 Trustees Of Tufts College Small Molecule Enhancer for Dendritic Cell Cancer Vaccines
WO2015069770A1 (en) * 2013-11-05 2015-05-14 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
FR2703251B3 (fr) 1993-03-31 1995-08-04 Vacsyn Sa Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine .
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
DK2112166T3 (en) 1998-12-23 2019-02-04 Pfizer Human monoclonal antibodies to CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
JP4249013B2 (ja) 2001-07-31 2009-04-02 佑 本庶 Ｐｄ−１に対し特異性を有する物質
IL164287A0 (en) 2002-04-12 2005-12-18 Medarex Inc Methods of treatment using ctla-4 antibodies
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
EP1793858A4 (en) 2004-09-08 2008-12-10 Univ Ohio State Res Found HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
EP1909758A1 (en) 2005-08-02 2008-04-16 I.D.M. Immuno-Designed Molecules Process for the preparation of liposomal formulations
WO2007058957A2 (en) 2005-11-10 2007-05-24 Point Therapeutics, Inc Boroproline compound and cytokine combination therapy
WO2007059099A2 (en) 2005-11-14 2007-05-24 Point Therapeutics, Inc. Boroproline combination therapy for cancer
EP1979488A4 (en) 2006-01-09 2009-05-27 Univ California IMMUNOSTIMULATING COMBINATIONS OF TNFRSF, TLR, NLR, RHR, PURINERIC RECEPTOR, AND CYTOKIN RECEPTOR ANTONISTS FOR VACCINES AND TUMOR IMMUNOTHERAPY
WO2008033368A2 (en) 2006-09-12 2008-03-20 Dara Biosciences, Inc. Boroproline compound and cytokine combination therapy
WO2008066729A2 (en) * 2006-11-22 2008-06-05 Dara Biosciences, Inc. Boronic acid containing compositions
US8603978B2 (en) 2006-12-01 2013-12-10 The United States of America, as represented by the Secretary, Department of Health and Humand Services Use of muramyl dipeptide (MDP) for treating inflammation
DK2644205T3 (en) 2007-04-12 2018-09-24 Brigham & Womens Hospital Inc Targeting ABCB5 for Cancer Therapy
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
ES2558568T3 (es) 2008-01-08 2016-02-05 Bristol-Myers Squibb Company Combinación de anticuerpo anti-CTLA4 con agentes moduladores de la tubulina para el tratamiento de enfermedades proliferativas
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
US8927697B2 (en) 2008-09-12 2015-01-06 Isis Innovation Limited PD-1 specific antibodies and uses thereof
AU2009290543B2 (en) 2008-09-12 2015-09-03 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
BRPI0919377A2 (pt) 2008-09-26 2016-09-27 Dana Farber Cancer Inst Inc anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
WO2010065711A1 (en) 2008-12-04 2010-06-10 Adimab, Inc. An abcb5 epitope and antibodies thereto for the treatment of cancer
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
CA3253628A1 (en) 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
CA2791930A1 (en) 2010-03-11 2011-09-15 Kerry Louise Tyson Pd-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
US8642557B2 (en) 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN107090029B (zh) 2010-11-11 2021-07-13 港大科桥有限公司 可溶性 pd-1变体、融合构建体及其用途
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
EP2694504A4 (en) 2011-04-08 2014-08-27 Afraxis Holdings Inc 8-ETHYL-6 (ARYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF DISEASES AFFECTING THE NERVOUS SYSTEM AND FOR THE TREATMENT OF CANCER
EA026924B1 (ru) 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
KR102243062B1 (ko) 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
JP6623353B2 (ja) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｐｄ−１抗体並びにその治療及び診断のための使用
CN104558177B (zh) 2013-10-25 2020-02-18 苏州思坦维生物技术股份有限公司 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
EP3066125A2 (en) * 2013-11-06 2016-09-14 Boehringer Ingelheim International GmbH Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents
CA2934028A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
JP7060324B2 (ja) * 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
CA2932515C (en) 2013-12-20 2023-08-01 Intervet International B.V. Caninized antibodies
DK3466949T3 (da) 2013-12-24 2021-03-15 Bristol Myers Squibb Co Tricyklisk forbindelse som anticancermidler
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
EA035259B1 (ru) 2014-02-14 2020-05-21 Иммьюн Дизайн Корп. Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
US10010587B2 (en) 2014-02-21 2018-07-03 Nektar Therapeutics IL-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
TWI703214B (zh) 2014-07-31 2020-09-01 中央研究院 具拮抗ｐｄ-１功能的適體分子於癌症治療相關之應用
HRP20201153T1 (hr) 2014-08-08 2021-01-22 The Board Of Trustees Of The Leland Stanford Junior University Pd-1 sredstva visokog afiniteta i načini uporabe
SI3179992T1 (sl) * 2014-08-11 2022-09-30 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
US10822414B2 (en) 2014-11-11 2020-11-03 Sutro Biopharma, Inc. Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies
US20160148513A1 (en) 2014-11-20 2016-05-26 Here Global B.V. Method and apparatus for providing line-of-sight obstruction notification for navigation
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
CA3175979A1 (en) 2014-12-22 2016-06-30 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
CN104479020B (zh) 2014-12-26 2019-08-02 上海复宏汉霖生物技术股份有限公司 一种抗pd-1人源抗体
CA2976446A1 (en) 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
CN104761633B (zh) 2015-03-25 2018-11-27 新乡学院 阻断猪pd-1/pd-l1通路的多肽及其应用
WO2016179576A1 (en) 2015-05-07 2016-11-10 Bioxcel Corporation Novel immunomodulatory therapeutic strategies targeting tumors in cancer
US20170000885A1 (en) 2015-06-08 2017-01-05 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
CN105061597B (zh) 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
MY193229A (en) 2015-06-16 2022-09-26 Merck Patent GmbH Pd-l1 antagonist combination treatments
CN116059219A (zh) 2015-07-16 2023-05-05 比奥克斯塞尔医疗股份有限公司 一种使用免疫调节治疗癌症的新颖方法
US11000521B2 (en) 2015-08-03 2021-05-11 Institut Pasteur Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
KR20180040706A (ko) 2015-09-01 2018-04-20 인네이트 튜머 이뮤니티, 인코포레이티드 면역억제 시토카인에 대해 증가된 면역 또는 저항성을 갖는 면역 세포 및 그의 용도
US10954300B2 (en) 2015-09-28 2021-03-23 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
US10183060B2 (en) 2015-10-01 2019-01-22 Heat Biologics, Inc. Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins
CN105175544B (zh) 2015-10-20 2021-04-09 安徽瀚海博兴生物技术有限公司 一种抗pd-1人源化单克隆抗体及其应用
WO2017079303A1 (en) 2015-11-02 2017-05-11 The Cleveland Clinic Foundation Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer
KR102762431B1 (ko) 2016-01-08 2025-02-03 레플리뮨 리미티드 변형된 항종양 바이러스
US20190008918A1 (en) 2016-03-08 2019-01-10 Bioxcel Corporation Immunomodulation therapies for cancer
US11583516B2 (en) 2016-09-07 2023-02-21 Trustees Of Tufts College Dash inhibitors, and uses related thereto
LT3512547T (lt) 2016-09-14 2021-01-11 Abbvie Biotherapeutics Inc. Antikūnai prieš pd-1
US11613785B2 (en) 2017-01-09 2023-03-28 Onkosxcel Therapeutics, Llc Predictive and diagnostic methods for prostate cancer
WO2019094916A1 (en) 2017-11-13 2019-05-16 Bioxcel Therapeutics, Inc. Methods and compositions for treating cancer by modifying multiple arms of the immune system
EP3893888A4 (en) 2018-12-10 2022-08-31 Bioxcel Therapeutics, Inc. COMBINATION THERAPIES FOR TREATING DISEASES USING AN INNATE IMMUNITY MODIFIER AND AN OX40 AGONIST
US20220089733A1 (en) 2018-12-10 2022-03-24 Bioxcel Therapeutics, Inc. Novel approach for treatment of cancer using immunomodulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127204A2 (en) * 2006-04-24 2007-11-08 Dara Biosciences, Inc. Methods and compositions relating to immunostimulation
US20140271725A1 (en) * 2011-11-22 2014-09-18 Trustees Of Tufts College Small Molecule Enhancer for Dendritic Cell Cancer Vaccines
WO2014144600A2 (en) * 2013-03-15 2014-09-18 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
WO2015069770A1 (en) * 2013-11-05 2015-05-14 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C. CUNNINGHAM et al. Phase 2 trial of talabostat and cisplatin in patients with stage IV melanoma. Journal of Clinical Oncology 24, no. 18_suppl (June 20 2006) 8040-8040. *

Also Published As

Publication number Publication date
MX2018000619A (es) 2019-03-06
EP3322448A1 (en) 2018-05-23
CA2991628C (en) 2020-04-07
AU2016293674B2 (en) 2019-11-21
CN108136025A (zh) 2018-06-08
RU2018105985A3 (enExample) 2019-08-16
MA42459A (fr) 2018-05-23
AU2016293674A1 (en) 2018-02-22
AU2020200953B2 (en) 2021-12-23
RU2019144144A (ru) 2020-03-19
JP7032311B2 (ja) 2022-03-08
JP2018521135A (ja) 2018-08-02
WO2017011831A1 (en) 2017-01-19
CN116059218A (zh) 2023-05-05
NZ739503A (en) 2023-06-30
CA2991628A1 (en) 2017-01-19
AU2020200953A1 (en) 2020-02-27
US20170266280A1 (en) 2017-09-21
BR112018000917A2 (pt) 2018-09-11
US20240000928A1 (en) 2024-01-04
AU2022201950A1 (en) 2022-04-14
RU2018105985A (ru) 2019-08-16
HK1248115A1 (zh) 2018-10-12
EP3322448A4 (en) 2019-03-06
MX2022010270A (es) 2022-09-19
ZA201903442B (en) 2021-04-28
CN108136025B (zh) 2022-09-06
KR20180036974A (ko) 2018-04-10
ZA201800688B (en) 2020-08-26
US20250213681A1 (en) 2025-07-03
CN116059219A (zh) 2023-05-05
US11564986B2 (en) 2023-01-31

Similar Documents

Publication Publication Date Title
RU2711380C2 (ru) Новый подход к лечению рака с применением иммуномодуляции
JP7569166B2 (ja) Ｐｄ－１に対する抗体分子およびその使用
JP7506981B2 (ja) Ｔｌｒ７アゴニストを含む併用薬
JP2018522027A (ja) Ｐｄ−１に対する抗体分子を含む組み合わせ治療
KR20240110996A (ko) 면역 관문 저해제와 조합한 플리나불린의 용도
JP2021502423A (ja) 免疫系の複数のアームを修飾することによってがんを治療するための方法及び組成物
TW202220654A (zh) 用於治療癌症之組合
CN119816313A (zh) 含有抗人表皮生长因子受体2（her2）嵌合抗原受体（car）的自然杀伤细胞的给药方法
TW201712035A (zh) 基於過敏反應素－１拮抗劑之癌免疫增強劑
US20220025061A1 (en) Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
RU2817047C2 (ru) Новый подход к лечению рака с применением иммуномодуляции
US20240182568A1 (en) Methods of enhancing antibody therapies
CA3007671C (en) Antibody molecules to pd-1 and uses thereof
HK40119904A (zh) 含有抗人表皮生长因子受体2(her2)嵌合抗原受体(car)的自然杀伤细胞的给药方法
HK1255016B (zh) 通过组合疗法治疗实体或淋巴肿瘤的方法
HK1255016A1 (en) Methods of treating solid or lymphatic tumors by combination therapy